AtriCure Inc (ATRC)

15.31
NASDAQ : Health Care
Prev Close 15.24
Day Low/High 15.00 / 15.32
52 Wk Low/High 13.44 / 28.15
Avg Volume 247.80K
Exchange NASDAQ
Shares Outstanding 33.09M
Market Cap 504.35M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AtriCure Receives CE Mark For The AtriClip® PRO2 Device

AtriCure Receives CE Mark For The AtriClip® PRO2 Device

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received CE Mark for the AtriClip PRO2 Left Atrial...

First Week of ATRC August 19th Options Trading

First Week of ATRC August 19th Options Trading

Investors in AtriCure Inc saw new options become available this week, for the August 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ATRC options chain for the new August 19th contracts and identified one put and one call contract of particular interest.

AtriCure Announces The First Patient Enrolled In The FROST Cryoanalgesia Study

AtriCure Announces The First Patient Enrolled In The FROST Cryoanalgesia Study

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient has been enrolled in the FROST study...

These 5 Stocks Are Poised for Breakouts

These 5 Stocks Are Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Commit To Purchase AtriCure At $12.50, Earn 13.3% Annualized Using Options

Commit To Purchase AtriCure At $12.50, Earn 13.3% Annualized Using Options

Investors considering a purchase of AtriCure Inc shares, but tentative about paying the going market price of $14.08/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $12.50 strike, which has a bid at the time of this writing of 70 cents.

AtriCure Becomes Oversold (ATRC)

AtriCure Becomes Oversold (ATRC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AtriCure Suffers From Weak Chart, Downgrade

We are not optimistic about the next few months.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABCD, ABX, AEG, AMBC, AZN, BK, CBG, CBT, CNA, CSTE, DO, EEP, GBX, GRC, HHC, NWFL, OFIX, RJF, ROG, RVSB, SBAC, SCCO, SLM, TOT Downgrades: ATRC, BSFT, CZNC, PCRX, VICR, WTM Initiations: RYAM Read on to get TheStreet Quant Ratings' detailed report:

AtriCure To Present At The UBS Global Healthcare Conference

AtriCure To Present At The UBS Global Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the UBS Global Healthcare Conference at the Grand...

AtriCure Reports First Quarter 2016 Financial Results

AtriCure Reports First Quarter 2016 Financial Results

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced first quarter 2016 financial results.

AtriCure Announces $25 Million Term Loan With Silicon Valley Bank

AtriCure Announces $25 Million Term Loan With Silicon Valley Bank

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has entered into an amended and restated term loan and revolving...

AtriCure Receives FDA Clearance For New AtriClip® Device

AtriCure Receives FDA Clearance For New AtriClip® Device

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced U.

AtriCure Announces 510(k) Clearance For The CryoFORM™ Cryoablation Probe

AtriCure Announces 510(k) Clearance For The CryoFORM™ Cryoablation Probe

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received 510(k) clearance for the cryoFORM...

AtriCure To Announce First Quarter 2016 Financial Results

AtriCure To Announce First Quarter 2016 Financial Results

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the first quarter of 2016 on Thursday, April 28,...

5 Breakout Stocks to Buy Off Weakness

5 Breakout Stocks to Buy Off Weakness

These stocks are within range of triggering big breakouts. Here's how to trade them now.

AtriCure Reports Fourth Quarter And Full Year 2015 Financial Results

AtriCure Reports Fourth Quarter And Full Year 2015 Financial Results

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced fourth quarter and full year 2015 financial results.

Commit To Purchase AtriCure At $15, Earn 17.3% Annualized Using Options

Commit To Purchase AtriCure At $15, Earn 17.3% Annualized Using Options

Investors eyeing a purchase of AtriCure Inc stock, but cautious about paying the going market price of $17.28/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $15 strike, which has a bid at the time of this writing of $1.05.

AtriCure Enrolls First Patient In Randomized Multi-Center Trial Evaluating Post-Operative Afib

AtriCure Enrolls First Patient In Randomized Multi-Center Trial Evaluating Post-Operative Afib

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, announced today that the first patient was enrolled and treated at PinnacleHealth...

Oversold Conditions For AtriCure (ATRC)

Oversold Conditions For AtriCure (ATRC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AtriCure To Announce Fourth Quarter And Full Year 2015 Financial Results

AtriCure To Announce Fourth Quarter And Full Year 2015 Financial Results

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the fourth quarter and full year 2015 on Tuesday,...

AtriCure To Present At The Leerink Global Healthcare Conference

AtriCure To Present At The Leerink Global Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Leerink Global Healthcare Conference at the...

AtriCure Announces Approval For The AtriClip In Japan

AtriCure Announces Approval For The AtriClip In Japan

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of...

Oversold Conditions For AtriCure (ATRC)

Oversold Conditions For AtriCure (ATRC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

AtriCure Announces Preliminary Results For Fourth Quarter And Full Year 2015 Updates 2016 Guidance

AtriCure Announces Preliminary Results For Fourth Quarter And Full Year 2015 Updates 2016 Guidance

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced preliminary financial results for fourth quarter and full year 2015 and...

AtriCure Announces The First Patient Enrolled In International Afib Study

AtriCure Announces The First Patient Enrolled In International Afib Study

AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient has been enrolled in the CEASE ( Combined...

AtriCure To Present At The Piper Jaffray Healthcare Conference

AtriCure To Present At The Piper Jaffray Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Piper Jaffray Healthcare Conference at the...

Commit To Buy AtriCure At $17.50, Earn 12.7% Annualized Using Options

Commit To Buy AtriCure At $17.50, Earn 12.7% Annualized Using Options

Investors eyeing a purchase of AtriCure Inc stock, but cautious about paying the going market price of $20.67/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2016 put at the $17.50 strike, which has a bid at the time of this writing of 95 cents.

Today's Weak On High Volume Stock: AtriCure (ATRC)

Today's Weak On High Volume Stock: AtriCure (ATRC)

Trade-Ideas LLC identified AtriCure (ATRC) as a weak on high relative volume candidate